$6 might be way too much to pay for msb soon, page-4

With $260m in the bank and Teva funding trails on a number of their products, I dont think the financial position is weak at all. In fact, it is the cash position and the backing of a large pharma which justifies its price.

I suspect we will soon see another pharma come to the p[arty and fund the diabetes trials.

So, I am very curious as to why you would suggest the financial position to be weak.

In my view, the greatest value MSB have is their gobal stem cell patent which is why the likes of Cephalon and Teva are willing to fund and hold a stake in the group.